腹腔镜左胰腺切除术治疗放化疗后胰腺导管腺癌安全性与开腹相当
单中心回顾性研究纳入2012至2024年间57例接受新辅助放化疗后行左胰腺切除术的胰腺导管腺癌患者,其中腹腔镜22例、开腹35例。腹腔镜组术中出血、手术时间和住院时间均优于开腹组,而Clavien III-IV并发症、死亡率、B/C级胰瘘、肿瘤大小、淋巴结清扫数、R0切除率及3年和5年生存率两组相当。结论认为新辅助放化疗不损害腹腔镜手术的优势。
要点
- 新辅助放化疗后腹腔镜左胰腺切除术出血更少、手术时间和住院时间更短。
- 两组Clavien III-IV并发症、死亡率、B/C级胰瘘及R0切除率无显著差异。
- 两组3年和5年总生存及无病生存可比,肿瘤学结局相当。
核心结论
- 新辅助放化疗不损害腹腔镜左胰腺切除术的优势,其手术和肿瘤学结局与开腹左胰腺切除术相当。
研究设计与样本
- 单中心回顾性队列研究,纳入2012至2024年间接受新辅助放化疗后行左胰腺切除术的胰腺导管腺癌患者57例,其中腹腔镜组22例(39%)、开腹组35例(61%)。
主要发现
- 腹腔镜组较开腹组中位出血量更少(100 vs. 300 mL,p=0.002),中位手术时间更短(210 vs. 255 min,p=0.003),中位住院时间更短(8 vs. 14天,p<0.001)。
- 两组Clavien III-IV并发症发生率(0 vs. 9%,p=0.276)、死亡率(0% vs. 6%,p=0.518)和B/C级术后胰瘘发生率(0 vs. 3%,p=1.00)相似。
- 两组中位肿瘤大小(25 vs. 21 mm,p=0.657)、中位淋巴结清扫数(15 vs. 21,p=0.185)和R0切除率(均为86%,p=1.00)相似。
- 两组3年和5年总生存及无病生存可比。
临床怎么用
- 对于接受新辅助放化疗的胰体尾胰腺导管腺癌患者,腹腔镜左胰腺切除术可作为开腹手术的可行选择,不增加短期并发症或损害肿瘤学结局。
局限性
- 单中心回顾性研究,样本量较小(57例),可能存在选择偏倚,结论需更大样本前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemoradiotherapy (NACRT) has become a standard in the treatment of borderline and locally advanced pancreatic ductal adenocarcinomas (PDAC). Left pancreatectomy (LP) is the procedure of choice for body and tail PDAC. Only a few data compare the outcomes of laparoscopic and open LP (LLP, OLP) after NACRT. METHODS: A monocentric retrospective cohort of patients who underwent LLP or OLP for PDAC after NACRT between 2012 and 2024. RESULTS: We included 57 patients, 22 LLP (39%) and 35 OLP (61%) with no difference regarding demographic characteristics. LLP compared to OLP showed less median blood loss (100 vs. 300 mL, p = 0.002), shorter median operative time (210 vs. 255 min, p = 0.003), and median length of stay (8 vs. 14 days, p < 0.001). Rates of Clavien III-IV complications (0 vs. 9%; p = 0.276), mortality (0% vs. 6%, p = 0.518) and grade B/C postoperative pancreatic fistula (0 vs. 3%; p = 1.00) were similar. Median tumor size (25 vs. 21 mm, p = 0.657), median number of harvested lymph nodes (15 vs. 21, p = 0.185), and R0 resection rate (86% for both, p = 1.00) were similar as well. Three-year and five-year overall and disease-free survival were comparable. CONCLUSION: NACRT does not seem to compromise the benefits of laparoscopic surgery as LLP has comparable surgical and oncological outcomes compared to OLP.
引用
- Vlasceanu A, Karam E, Aussilhou B, et al. Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectomy: a single-center retrospective study. Surg Endosc. 2026. PMID: 42627533. doi:10.1007/s00464-026-12991-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。